Patents Assigned to SomaGenics Inc.
-
Patent number: 11319538Abstract: Wound healing is a complex homeostatic process in which several distinct types coordinate to repair a physical damage. Failure to close wounds contributes to the pathology of conditions like diabetes mellitus, particularly in the elderly. Presented herein are molecules, pharmaceutical compositions, and methods for applying small RNA oligonucleotide technology to wound healing. Small RNA oligonucleotide approaches as disclosed herein provide a therapeutic strategy for improving both basal and pathological wound healing.Type: GrantFiled: September 5, 2019Date of Patent: May 3, 2022Assignee: SOMAGENICS, INC.Inventors: Anne Dallas, Heini Ilves, Sumedha Jayasena, Brian H. Johnston
-
Patent number: 10870850Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.Type: GrantFiled: October 5, 2017Date of Patent: December 22, 2020Assignee: SOMAGENICS, INC.Inventors: Qing Ge, Brian H. Johnston, Mark A. Behlke, Heini Ilves, Anne Dallas
-
Patent number: 10450569Abstract: Wound healing is a complex homeostatic process in which several distinct types coordinate to repair a physical damage. Failure to close wounds contributes to the pathology of conditions like diabetes mellitus, particularly in the elderly. Presented herein are molecules, pharmaceutical compositions, and methods for applying small RNA oligonucleotide technology to wound healing. Small RNA oligonucleotide approaches as disclosed herein provide a therapeutic strategy for improving both basal and pathological wound healing.Type: GrantFiled: August 12, 2016Date of Patent: October 22, 2019Assignee: SOMAGENICS, INC.Inventors: Anne Dallas, Heini Ilves, Sumedha Jayasena, Brian H. Johnston
-
Patent number: 10041107Abstract: Currently, the circularization of small RNAs is broadly regarded as an obstacle in ligation-related assays and explicitly avoided while short lengths of linear RNA targets is broadly recognized as a factor limiting use of conventional primers in PCR-related assays. In contrast, the disclosed invention capitalizes on circularization of small RNA targets or their conjugates with oligonucleotide adapters. The circular RNA templates provide amplification of the target sequences via synthesis of multimer nucleic acids that can be either labeled for direct detection or subjected to PCR amplification and detection. Structure of small circular RNAs and corresponding multimeric nucleic acids provide certain advantages over current methods including flexibility in design of conventional RT and PCR primers as well as use of 5?-overlapping dimer-primers for efficient and sequence-specific amplification of short target sequences.Type: GrantFiled: October 6, 2016Date of Patent: August 7, 2018Assignee: SOMAGENICS, INC.Inventors: Sergei A. Kazakov, Pavan Kumar, Brian H. Johnston
-
Patent number: 9816130Abstract: Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) are disclosed herein. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used to attach adapters and/or linkers to target RNAs. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used in reactions, including, but not limited to, ligation reactions, amplification reactions, and sequencing reactions. Additionally, methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used for reducing and/or preventing the formation of secondary structures in target RNAs. These methods, compositions, and kits can also find use in a number of applications, for example, any application that benefits from stabilizing primary RNA structure, such as detecting and quantifying target RNAs in a sample, in the construction of small RNA libraries, in microarray and RT-qPCR applications, etc.Type: GrantFiled: December 21, 2012Date of Patent: November 14, 2017Assignee: SOMAGENICS, INC.Inventor: Sergei A. Kazakov
-
Patent number: 9816091Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.Type: GrantFiled: October 3, 2014Date of Patent: November 14, 2017Assignee: SOMAGENICS, INC.Inventors: Qing Ge, Brian H. Johnston, Mark A. Behlke, Heini Ilves, Anne Dallas
-
Patent number: 9809847Abstract: Disclosed herein are compositions and methods for the processing, amplification and detection of polynucleotides using target-specific oligonucleotides (TSOs). Hybridization of TSOs to target polynucleotides guides target processing into and purification of small target fragments that then can be amplified and detected with high sensitivity and reproducibility. The method is specifically beneficial for highly degraded polynucleotides found in biological samples.Type: GrantFiled: June 19, 2015Date of Patent: November 7, 2017Assignee: SOMAGENICS, INC.Inventors: Sergei A. Kazakov, Catharina Casper-Lindley, Anne Dallas, Heini Ilves, Brian H. Johnston
-
Publication number: 20170121762Abstract: Disclosed herein are compositions and methods for the processing, amplification and detection of polynucleotides using target-specific oligonucleotides (TSOs). Hybridization of TSOs to target polynucleotides guides target processing into and purification of small target fragments that then can be amplified and detected with high sensitivity and reproducibility. The method is specifically beneficial for highly degraded polynucleotides found in biological samples.Type: ApplicationFiled: June 19, 2015Publication date: May 4, 2017Applicant: SomaGenics, Inc.Inventors: Sergei A. KAZAKOV, Catharina CASPER-LINDLEY, Anne DALLAS, Heini ILVES, Brian H. JOHNSTON
-
Patent number: 9493818Abstract: Currently, the circularization of small RNAs is broadly regarded as an obstacle in ligation-related assays and explicitly avoided while short lengths of linear RNA targets is broadly recognized as a factor limiting use of conventional primers in PCR-related assays. In contrast, the disclosed invention capitalizes on circularization of small RNA targets or their conjugates with oligonucleotide adapters. The circular RNA templates provide amplification of the target sequences via synthesis of multimer nucleic acids that can be either labeled for direct detection or subjected to PCR amplification and detection. Structure of small circular RNAs and corresponding multimeric nucleic acids provide certain advantages over current methods including flexibility in design of conventional RT and PCR primers as well as use of 5?-overlapping dimer-primers for efficient and sequence-specific amplification of short target sequences.Type: GrantFiled: August 25, 2015Date of Patent: November 15, 2016Assignee: SOMAGENICS, INC.Inventors: Sergei A. Kazakov, Pavan Kumar, Brian H. Johnston
-
Patent number: 9416402Abstract: Currently, the circularization of small RNAs is broadly regarded as an obstacle in ligation-related assays and explicitly avoided while short lengths of linear RNA targets is broadly recognized as a factor limiting use of conventional primers in PCR-related assays. In contrast, the disclosed invention capitalizes on circularization of small RNA targets or their conjugates with oligonucleotide adapters. The circular RNA templates provide amplification of the target sequences via synthesis of multimer nucleic acids that can be either labeled for direct detection or subjected to PCR amplification and detection. Structure of small circular RNAs and corresponding multimeric nucleic acids provide certain advantages over current methods including flexibility in design of conventional RT and PCR primers as well as use of 5?-overlapping dimer-primers for efficient and sequence-specific amplification of short target sequences.Type: GrantFiled: January 20, 2015Date of Patent: August 16, 2016Assignee: SOMAGENICS, INC.Inventors: Sergei A. Kazakov, Pavan Kumar, Brian H. Johnston
-
Patent number: 8962253Abstract: Currently, the circularization of small RNAs is broadly regarded as an obstacle in ligation-related assays and explicitly avoided while short lengths of linear RNA targets is broadly recognized as a factor limiting use of conventional primers in PCR-related assays. In contrast, the disclosed invention capitalizes on circularization of small RNA targets or their conjugates with oligonucleotide adapters. The circular RNA templates provide amplification of the target sequences via synthesis of multimer nucleic acids that can be either labeled for direct detection or subjected to PCR amplification and detection. Structure of small circular RNAs and corresponding multimeric nucleic acids provide certain advantages over current methods including flexibility in design of conventional RT and PCR primers as well as use of 5?-overlapping dimer-primers for efficient and sequence-specific amplification of short target sequences.Type: GrantFiled: April 13, 2010Date of Patent: February 24, 2015Assignee: Somagenics Inc.Inventors: Sergei A. Kazakov, Pavan Kumar, Brian H. Johnston
-
Publication number: 20150051099Abstract: Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) are disclosed herein. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used to attach adapters and/or linkers to target RNAs. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used in reactions, including, but not limited to, ligation reactions, amplification reactions, and sequencing reactions. Additionally, methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used for reducing and/or preventing the formation of secondary structures in target RNAs. These methods, compositions, and kits can also find use in a number of applications, for example, any application that benefits from stabilizing primary RNA structure, such as detecting and quantifying target RNAs in a sample, in the construction of small RNA libraries, in microarray and RT-qPCR applications, etc.Type: ApplicationFiled: December 21, 2012Publication date: February 19, 2015Applicant: SomaGenics, Inc.Inventor: Sergei A. Kazakov
-
Patent number: 8871730Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.Type: GrantFiled: July 13, 2010Date of Patent: October 28, 2014Assignee: SomaGenics Inc.Inventors: Qing Ge, Brian H. Johnston, Mark A. Behlke, Heini Ilves, Anne Dallas
-
Patent number: 8779115Abstract: Methods, compositions, and kits that include small hairpin RNA (shRNA) useful for inhibition of gene expression, such as viral-mediated gene expression, are described.Type: GrantFiled: August 22, 2012Date of Patent: July 15, 2014Assignee: Somagenics Inc.Inventors: Qing Ge, Brian H. Johnston, Sergei A Kazakov, Heini Ilves, Anne Dallas
-
Patent number: 8426380Abstract: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.Type: GrantFiled: March 2, 2011Date of Patent: April 23, 2013Assignee: Somagenics, Inc.Inventors: Roger L. Kaspar, Heini Ilves, Attila A. Seyhan, Alexander V. Vlassov, Brian H. Johnston
-
Patent number: 8283460Abstract: Methods, compositions, and kits that include small hairpin RNA (shRNA) useful for inhibition of gene expression, such as viral-mediated gene expression, are described.Type: GrantFiled: October 14, 2009Date of Patent: October 9, 2012Assignee: Somagenics, Inc.Inventors: Qing Ge, Brian H. Johnston, Sergei A. Kazakov, Heini Ilves, Anne Dallas
-
Patent number: 7902351Abstract: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.Type: GrantFiled: June 1, 2006Date of Patent: March 8, 2011Assignee: SomaGenics Inc.Inventors: Roger L. Kaspar, Heini Ilves, Attila A. Seyhan, Alexander V. Vlassov, Brian H. Johnston
-
Publication number: 20090170794Abstract: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) which are useful for inhibition of viralmediated gene expression. Small interfering RNAs as described herein may be used in methods of treatment of HCV infection. ShRNA and siRNA constructs that target the internal ribosome entry site (IRES) sequence of HCV are described.Type: ApplicationFiled: September 12, 2005Publication date: July 2, 2009Applicant: SomaGenics Inc.Inventors: Roger L. Kaspar, Heine Ilves, Attila A. Seyhan, Alexander V. Vlassov, Brian H. Johnston
-
Publication number: 20070105108Abstract: The invention provides allosterically regulatable polynucleotides capable of target-dependent circularization and topological linkage to a target nucleic acid molecule. Polynucleotides of the invention include a target binding sequence and a regulatory element which prevents circularization in the absence of the target binding. Polynucleotides may include a catalytic domain, allowing circularization to proceed via catalysis when the target binding sequence of the polynucleotide is bound to the target. Topologically linked polynucleotides may be used for detection of target molecules or to inhibit transcription or translation of the target.Type: ApplicationFiled: June 25, 2004Publication date: May 10, 2007Applicant: Somagenics, Inc.Inventors: Sergei Kazakov, Anne Dallas, Tai-Chih Kuo, Brian Johnston
-
Publication number: 20060074041Abstract: The present invention is directed to novel nucleic acid molecules and methods for their use. More specifically, the novel nucleic acid molecules of the present invention are capable of tightly and specifically interacting with a target molecule of interest not only through standard Watson-Crick base pairing, but also through additional features which allow the antisense molecules to become topologically “locked” onto the target nucleic acid, thereby imparting improved transcription and translation inhibitory properties.Type: ApplicationFiled: September 16, 2005Publication date: April 6, 2006Applicant: Somagenics, Inc.Inventors: Brian Johnston, Sergei Kazakov, Kevin Kisich